News

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical trial recruitment is on track, and additional international clinical sites are set to open for OCTOPOD-IV US trial (OCTOPOD-IP) utilising intraperitoneal delivery has been initiated   Oxford UK, October 13, 2025.   Theolytics, a clinical-stage biotechnology company developing next-gene

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, October 7, 2025.   Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulat

David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer. Oxford UK, December 17, 2024.  Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced the appointment of biotechnology industry leader David Apelian M

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for intravenous delivery, THEO-260 lyses cancer cells and cancer-associated fibroblasts whilst alleviating immune suppression in preclinical studies. The Phase I/IIa trial is designed to investigate the safety and tolerability of THEO-260 administered via intravenous delivery and det

The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic (cancer cells and CAFs) and immunotherapeutic mechanism of action Oxford UK September 2nd 2024. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Thera

Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and The University of Oxford. New funding enables Theolytics to advance lead candidate THEO-260 through to clinical proof of concept Phase 1 clinical trial for THEO-260 in ovarian cancer planned to start this year   Oxford, UK April 17th, 2024 Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today a

Mike brings decades of operational and board experience gained in Pharma, Biotech and Venture Capital to Theolytics Oxford, UK, March 21st 2024 Theolytics, a biotechnology company developing  category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell, who is retiring from the Board having served as Chair since 2019.   This appointment comes at a pivotal time for Theolytics as the Compa

Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer ahead of first in human clinical trials anticipated

Oxford, UK, 9 June 2023 - Theolytics, a biotechnology company harnessing viruses to combat disease, today announces data presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held 2 to 6 June, 2023 in Chicago and at the European Hematology Association (EHA) 2023 Congress, which is being held 8 to 11 June in Frankfurt. ASCO Abstract Title: Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours Vie

Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel therapy for multiple myeloma patients in need Oxford, UK, 1st June 2022 Theolytics is a biotechnology company harnessing viruses to combat disease. The company has been awarded a Biomedical catalyst grant by Innovate UK to progress a novel therapy for multiple myeloma patients. Multiple myeloma is an incurable blood cancer, for which cancer-kill

We’re delighted to announce that we’re all taking part in the BioIndustry Association’s Research Relay 2021 to raise money for Ovarian Cancer Action . As a team, we’re committing to walking 2000km throughout the month of May so Ovarian Cancer Action can continue their brilliant work in the fight against a cancer that affects 295,000 women every year. The disease is difficult to detect early and complicated to treat, meaning half of these women will not survive beyond five ye

Theolytics has been awarded a grant by Innovate UK, the UK’s innovation agency, to optimise their oncolytic virus candidate for treatment of ovarian cancer. November 6th, 2020 Theolytics, an Oxford-based biotech start-up focused on harnessing viruses to fight cancer through Darwinian selection methods, has been awarded a grant by Innovate UK, the UK’s innovation agency, to optimise their oncolytic virus candidate for treatment of ovarian cancer. This grant, from Innovate UK’s

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies. Oxford, UK, 7th January 2020 Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $6.8 million (UK £5 million) Series A round. The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI). The financing will be used to progress t